RxDoctor Payments Data

Kristy Washinger

Nurse Practitioner · Camp Hill, PANPI 1447580873

Payments from drug & device makers

$2,651in general payments, 2019–2025

Across 118 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$1K
  • Amgen$318
  • AstraZeneca$272
  • Fresenius USA Marketing, Inc.$265
  • Akebia Therapeutics Inc$204
  • Vantive US Healthcare LLC$145
  • plus $137 from 3 others

What the payments were for

  • Food & beverage$2,651100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,651 in reported general payments places this provider in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$15,989
Medicare patients
94
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VeltassaPatiromer Calcium Sorbitex48$54,505
Sevelamer Carbonate213$34,802
VelphoroSucroferric Oxyhydroxide15$34,623
AuryxiaFerric Citrate14$16,289
Calcium Acetate85$5,526
Midodrine Hcl38$3,305
Carvedilol54$1,297
Bumetanide33$1,069
Hydralazine Hcl68$930
Nifedipine ErNifedipine19$542
Isosorbide Mononitrate ErIsosorbide Mononitrate30$536
Labetalol Hcl11$430
Amlodipine Besylate61$338
Calcitriol36$281
Minoxidil12$264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$265$34,62315 claims
Akebia Therapeutics IncAuryxia$204$16,28914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Camp Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →